Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
MINZOYA vs ALYACEN 1/35
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Zinc pyrithione is an antimicrobial agent that inhibits fungal growth by disrupting membrane transport and inhibiting mitochondrial function, leading to cell death.
Combination hormonal contraceptive: ethinyl estradiol suppresses gonadotropin release via negative feedback on hypothalamic-pituitary axis; norethindrone induces progestational effects including cervical mucus thickening and endometrial changes, inhibiting ovulation and sperm penetration.
Treatment of seborrheic dermatitis of the scalp,Treatment of dandruff (FDA-approved),Off-label: treatment of psoriasis of the scalp
Prevention of pregnancy
Intravenous infusion of 300 mg over 30 minutes every 4 weeks.
One tablet (norethindrone 1 mg and ethinyl estradiol 35 mcg) orally once daily for 21 consecutive days, followed by 7 days of placebo or no tablets.
Terminal elimination half-life of 20-30 hours; at steady state after 5-7 days, half-life reflects accumulation for once-daily dosing.
Norethindrone: 8-11 hours (terminal); ethinyl estradiol: 10-20 hours (terminal). The half-life supports once-daily dosing for oral contraceptive efficacy.
Not extensively metabolized; minimal systemic absorption after topical application.
Ethinyl estradiol: primarily hepatic via CYP3A4; norethindrone: hepatic reduction and sulfate conjugation.
Primarily hepatic metabolism with renal excretion of metabolites (50-60% as unchanged drug and conjugates); approximately 30-40% fecal elimination.
Renal excretion of metabolites (primarily ethinyl estradiol and norethindrone conjugates) accounts for approximately 50-60% of elimination; fecal excretion accounts for 30-40%. Unchanged drug excretion is minimal (<5%).
Approximately 95% bound, primarily to albumin and alpha-1-acid glycoprotein.
Norethindrone: 61% bound to albumin and SHBG; ethinyl estradiol: 97-98% bound to albumin.
0.5-0.8 L/kg, consistent with distribution into total body water and some tissue binding.
Norethindrone: 3.8-4.5 L/kg; ethinyl estradiol: 2.0-4.0 L/kg. Large Vd indicates extensive tissue distribution.
Oral bioavailability of 70-80% due to first-pass metabolism; food does not significantly affect absorption.
Oral: Norethindrone ~64%, ethinyl estradiol ~38-48% (due to first-pass metabolism).
No dose adjustment required for mild to moderate renal impairment. Not studied in severe renal impairment (Cr Cl <30 m L/min).
No dose adjustment required for mild to moderate renal impairment. Contraindicated in severe renal impairment or acute renal failure due to potential fluid retention and electrolyte disturbances.
No dose adjustment required for mild to moderate hepatic impairment (Child-Pugh A or B). Not studied in severe hepatic impairment (Child-Pugh C).
Contraindicated in patients with hepatic impairment, including Child-Pugh class B or C, due to impaired metabolism of estrogen and progestin. Not recommended in patients with active liver disease or history of liver tumors.
Safety and efficacy in pediatric patients have not been established. No recommended dose.
Not indicated for use before menarche. For postmenarchal adolescents, same dosing as adults. Safety and efficacy established for contraception; weight-based dosing not applicable.
No specific dose adjustment recommended based on age. Clinical studies included limited number of patients aged ≥65 years; no overall differences in safety or efficacy observed.
Not indicated for use after menopause due to lack of benefit and increased risks (e.g., cardiovascular, thromboembolic events). If used, monitor for fluid retention, hypertension, and glucose intolerance.
No FDA black box warning.
Cigarette smoking increases risk of serious cardiovascular events from combined oral contraceptives. Risk increases with age and heavy smoking (≥15 cigarettes/day). Women over 35 who smoke should not use this product.
For external use only. Avoid contact with eyes. If irritation occurs, discontinue use. May cause local skin reactions such as itching, burning, or erythema.
Thrombotic disorders (e.g., DVT, PE, stroke, MI),Cerebrovascular disease,Hepatic neoplasia,Gallbladder disease,Hypertension,Carbohydrate and lipid effects,Ocular lesions,Hereditary angioedema,Chloasma,Menstrual irregularities,Pregnancy exclusion prior to initiation
Hypersensitivity to zinc pyrithione or any component of the formulation.
Venous or arterial thrombotic/thromboembolic disease (current or history),Cerebrovascular disease,Coronary artery disease,Known or suspected breast cancer,Endometrial or other estrogen-dependent neoplasia,Undiagnosed abnormal genital bleeding,Cholestatic jaundice of pregnancy or jaundice with prior pill use,Hepatic adenoma or carcinoma,Known or suspected pregnancy,Hypersensitivity to any component,Smoking in women over 35
Minzoya has no specific food interactions; however, caution with high-tyramine foods (e.g., aged cheeses, cured meats, fermented products) is generally not required as Minzoya does not inhibit MAO-A. Grapefruit and grapefruit juice may increase mirtazapine levels; consider avoiding excessive consumption. Alcohol should be avoided due to additive sedation. Caffeine may counteract sedative effects.
No significant food interactions. Grapefruit juice may increase estrogen levels, but clinically not a concern. Avoid excessive alcohol, which may impair liver function and increase estrogen exposure. Maintain a healthy diet, as weight gain is possible.
Minzoya (misoprostol) is contraindicated in pregnancy due to proven teratogenicity. First trimester exposure is associated with Moebius syndrome, limb defects, and fetal death. Second and third trimester use is limited to induction of labor; risk of uterine hyperstimulation and fetal distress. Overall, pregnancy category X.
Pregnancy category X. Use of ALYACEN 1/35 (norethindrone/ethinyl estradiol) is contraindicated during pregnancy. First trimester: Increased risk of congenital anomalies, including cardiovascular defects and limb reduction defects. Second/third trimesters: Potential for urogenital abnormalities and feminization of male fetus. Exposure is associated with subsequent development of clear cell adenocarcinoma of vagina/cervix in female offspring (DES-related).
Misoprostol is excreted into human breast milk; M/P ratio is not established. Peak milk levels occur 1 hour after maternal ingestion. No adverse effects on infants have been reported, but the manufacturer recommends caution. Limited data; avoid prolonged use during breastfeeding.
Small amounts of contraceptive steroids and/or metabolites have been identified in breast milk. M/P ratio: Not specifically determined for this combination; ethinyl estradiol M/P ratio ~0.02-0.04. Use may reduce milk production and quality. Breastfeeding not recommended during use. Alternative contraception advised.
Dosing adjustments not required for pregnancy per se; however, the drug is contraindicated in pregnancy except for specific obstetric indications. For induction of labor, use lower doses (25-50 mcg) compared to non-pregnant use. For postpartum hemorrhage, standard dose is 800-1000 mcg rectally or sublingually; no adjustment for pregnancy itself.
Contraindicated in pregnancy; no dose adjustments applicable. Discontinue medication immediately upon pregnancy detection.
Minzoya (mirtazapine) is a noradrenergic and specific serotonergic antidepressant (Na SSA). It is particularly useful for patients with insomnia and poor appetite due to its sedative and appetite-stimulating effects. Monitor for weight gain, especially with long-term use. Avoid concomitant use with MAOIs; allow a 14-day washout. Dosing at bedtime minimizes daytime sedation. Anticholinergic effects are minimal; however, caution in patients with hepatic impairment (dose reduction recommended) and elderly patients due to increased risk of falls from orthostatic hypotension. Rare but serious adverse effects include agranulocytosis (monitor for infection). Onset of therapeutic effect is typically 2-4 weeks.
ALYACEN 1/35 is a combination oral contraceptive containing ethinyl estradiol 35 mcg and norgestimate 1 mg. It is indicated for the prevention of pregnancy and for the treatment of moderate acne vulgaris in females ≥15 years of age who desire an oral contraceptive. Monitor for thromboembolic events, especially in smokers over 35 or those with migraine with aura. Use with caution in patients with liver impairment or history of cholestatic jaundice. The pill-free interval should not exceed 7 days; missed pills increase ovulation risk. Consider non-hormonal backup if vomiting or diarrhea occurs within 4 hours of dosing.
Take Minzoya exactly as prescribed, usually once daily at bedtime due to its sedative effect.,Do not stop taking this medication abruptly without consulting your doctor, as withdrawal symptoms may occur.,Avoid alcohol and other central nervous system depressants while taking Minzoya, as they can increase sedation.,Report any signs of infection such as fever, sore throat, or mouth sores immediately, as this may indicate a low white blood cell count.,Weight gain and increased appetite are common; monitor your weight and discuss dietary adjustments with your healthcare provider.,May cause dizziness or drowsiness; avoid driving or operating heavy machinery until you know how this medication affects you.,If you miss a dose, skip the missed dose and take the next dose at the regular time. Do not double the dose.,Inform your doctor if you are pregnant, planning to become pregnant, or breastfeeding.,This medication may take several weeks to reach full effect; do not stop taking it without consulting your doctor.,Keep out of reach of children and store at room temperature away from moisture and heat.
Take one tablet daily at the same time each day; do not skip doses.,Use an additional non-hormonal contraceptive (e.g., condoms) if you miss a pill, have vomiting, or diarrhea.,Smoking while on this pill increases the risk of blood clots and stroke, especially if you are over 35.,Contact your healthcare provider immediately if you have chest pain, leg pain/swelling, sudden vision changes, or severe headache.,This medication does not protect against HIV or other sexually transmitted infections.,Store at room temperature, away from moisture and heat.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about MINZOYA vs ALYACEN 1/35, answered by our medical review team.
MINZOYA is a Oral Contraceptive that works by Zinc pyrithione is an antimicrobial agent that inhibits fungal growth by disrupting membrane transport and inhibiting mitochondrial function, leading to cell death.. ALYACEN 1/35 is a Oral Contraceptive that works by Combination hormonal contraceptive: ethinyl estradiol suppresses gonadotropin release via negative feedback on hypothalamic-pituitary axis; norethindrone induces progestational effects including cervical mucus thickening and endometrial changes, inhibiting ovulation and sperm penetration.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between MINZOYA and ALYACEN 1/35 depend on the specific clinical indication. These are both Oral Contraceptive agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of MINZOYA is: Intravenous infusion of 300 mg over 30 minutes every 4 weeks.. The standard adult dose of ALYACEN 1/35 is: One tablet (norethindrone 1 mg and ethinyl estradiol 35 mcg) orally once daily for 21 consecutive days, followed by 7 days of placebo or no tablets.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between MINZOYA and ALYACEN 1/35 in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. MINZOYA is classified as Category C. Minzoya (misoprostol) is contraindicated in pregnancy due to proven teratogenicity. First trimester exposure is associated with Moebius syndrome, limb defects, and fetal death. Sec. ALYACEN 1/35 is classified as Category C. Pregnancy category X. Use of ALYACEN 1/35 (norethindrone/ethinyl estradiol) is contraindicated during pregnancy. First trimester: Increased risk of congenital anomalies, including . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.